Loading...
NPI 1538113113 · Wakefield, RI · Mobile Radiology Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Rhode Island Pet Services, LLC is a mobile radiology clinic/center provider located in Wakefield, Rhode Island. This profile covers 4 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Rhode Island Pet Services, LLC |
| Address | 100 Kenyon Ave |
| City | Wakefield |
| State | RI |
| ZIP | 02879 |
| Taxonomy | Mobile Radiology Clinic/Center |
| NPI Enumerated | May 19, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $773.2K |
| Medicaid | $497.1K |
RHODE ISLAND PET SERVICES, LLC is a mobile radiology clinic focused on PET imaging services; its top Medicare codes are dominated by PET/CT–related radiopharmaceutical and imaging CPT/HCPCS codes (78815, A9595, A9552), which aligns with the provider taxonomy "Mobile Radiology Clinic/Center" and suggests operations are centered on diagnostic PET imaging and radiotracer administration rather than broad outpatient services. The presence of multiple FDG- and piflufolastat-related codes indicates both standard FDG PET studies and newer targeted diagnostic agents are part of their service mix.
Revenue concentration on Medicare is high: the precomputed top 3 Medicare codes by revenue account for 93.7% of this provider's total Medicare revenue, with 78815 alone representing $389.6K (50.4% of Medicare revenue). This concentration implies the provider’s Medicare business is heavily reliant on a small set of PET imaging services, making overall Medicare revenue sensitive to utilization or reimbursement changes for those specific codes.
On Medicaid, the provider is also concentrated: the top 3 Medicaid codes by revenue account for 100.0% of total Medicaid revenue, with 78815 generating $391.2K (78.7% of Medicaid revenue) and A9552 contributing $105.9K (21.3%). This indicates the provider’s Medicaid activity is nearly exclusively PET imaging and related radiotracer supply, reinforcing a single-service-line dependency across payers.
In absolute scale, lifetime Medicare revenue is $773.2K compared with lifetime Medicaid revenue of $497.1K, so Medicare represents the larger revenue source but Medicaid is a significant secondary payer; the provider is not single-payer dependent but has a concentrated dual-payer exposure centered on PET services.
Competitive standing for Medicare suggests this provider is a modest but not dominant national participant: 78815 ranks #526 of 6566 providers nationally (92nd percentile) and A9552 ranks in the 93rd percentile, both characterized in the source as "typical, unremarkable volume for this code," indicating routine but visible PET activity relative to national peers. For Medicaid in-state positions, 78815 ranks #2 of 3 providers (50th percentile) and A9552 ranks #2 of 2 providers (0th percentile), signaling limited in-state peer counts and a meaningful share of Medicaid PET billing in Rhode Island but not clear dominance.
Tenure: the provider’s NPI was enumerated on 2006-05-19 (approximately 20 years ago), indicating long-standing enrollment and likely established workflows and payer relationships for mobile PET imaging over two decades.
Payer-code mix and operational implications: high average paid/claim values for imaging and radiotracer codes (for example $1210 avg paid/claim for 78815 on Medicare and $1493 avg paid/claim for 78815 on Medicaid) suggest capital- and supply-intensive operations (scanner access, radiopharmaceutical handling, mobile logistics). The billing pattern—large proportions tied to PET/CT imaging and radiotracer doses—is consistent with a specialist imaging vendor rather than a general multispecialty outpatient provider.
Statistical standing notes: across Medicare codes the data labels each top code as "typical, unremarkable volume for this code" despite percentile placements, so while the provider has concentrated revenue in PET-related codes and ranks above many peers for some codes, its activity falls within expected ranges for specialized imaging providers nationally rather than representing an extreme outlier. On Medicaid, ranks reflect a small in-state provider pool which limits the interpretability of percentiles and suggests competitive context should be evaluated alongside absolute revenue and claim counts.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 320 | $1,210 | $389.6K |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | 430 | $490 | $206.1K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 310 | $410 | $128.8K |
| 78816 | The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The… | 40 | $1,220 | $48.6K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 260 | $1,490 | $391.2K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 310 | $350 | $105.9K |
How this provider's Medicaid billing volume and revenue compare to other Rhode Island providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Rhode Island median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 2 | 10 | 260 | $830 | $363.7K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 2 | 10 | 570 | $430 | $241.9K |
Other providers in the same ZIP code as Rhode Island Pet Services, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| South County Hospital Healthcare System | RI | General Acute Care Hospital | $0 | $5.3M |
| Eric Prosseda | RI | General Practice Dentistry | $0 | $5.2M |
| Joey Napolitano | RI | Public Health Dentistry | $0 | $1.7M |
| Elise Jarvis | RI | Mental Health Counselor | $0 | $1.7M |
| Catherine Degood | RI | Addiction Medicine (Family Medicine) Physician | $3.1K | $1.1M |
| Emergency Physician Associates Of New England PC | RI | Emergency Medicine Physician | $0 | $1M |
| Ira Kulman | RI | Clinical Neuropsychologist | $0 | $1M |
| South Kingstown School Department | RI | Local Education Agency (LEA) | $0 | $814K |
| Emily Colyer | RI | Emergency Medicine Physician | $36K | $528.6K |
| Town Of South Kingstown | RI | Land Ambulance | $338.7K | $217.5K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.